Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

US Patent 11267896 · Granted Mar 8, 2022

Estimated economic value: $4,218,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Activatable antibodies that bind epidermal growth factor receptor and methods of2025
Activatable antibodies that bind epidermal growth factor receptor and methods of2025
Methods of qualitatively and/or quantitatively analyzing properties of activatab2025
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and me2025
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and me2025
Activatable anti-CTLA-4 antibodies and uses thereof2025
Gene-edited natural killer cells2025
Genetically engineered T cells having improved persistence in culture2025
Modified urokinase-type plasminogen activator polypeptides and methods of use2025
Anti-CD38 binding domains2025
T-cells expressing anti-LIV1 chimeric antigen receptor2025
T-cells expressing anti-LIV1 chimeric antigen receptor2025